Medpace Inc

Description

Medpace has considerable experience in cardiovascular, CNS and diabetes Regenerative Medicine trials. Dr. Tom Todaro, Vice President, Medical Affairs-Cardiology has extensive experience in conducting clinical trials in cardiovascular disease including studies in complicated cardiovascular patients using stem cells in Acute Coronary Syndromes (ACS), and acute myocardial infarction (AMI). Likewise, Dr. Sam Kaba, Vice President, Neurology, is experienced in stem cell studies for stroke.

Innovative Technology, Personalized Service and Flexible, Integrated Data Our scientific and technical leaders provide guidance from the onset, reviewing protocols, advising on the best testing options, proposing optimum courier and shipping routes and delivering customized data solutions. From project managers, to medical technologists and laboratory scientists, to logistics teams, and data managers, Medpace is dedicated to providing the highest degrees of service and quality results.

Therapeutic – Global – Phase I thru IV For over 20 years, Medpace has helped sponsors accelerate global drug and device development through a full-service model.

Endocrine - Metabolic Disorders : Medpace has extensive experience in trial design, drug classes, and disease endpoints for Phase I-IV research in this area. Medpace's experience in conducting diabetes trials around the world is unmatched by any other Clinical Research Organization (CRO).

Regenerative medicine holds the bold promise of discovering new therapeutic approaches to combat diseases that are still out of reach of traditional drugs and biologicals. From cell therapies to tissue engineering, these novel therapeutic models involve human tissue, device combinations, and delivery methods that make regenerative medicine a very complex target of clinical development. The complexity of developing regenerative medicine products requires a committed and experienced partner.

Fact sheet

Products & services

Similar companies nearby